Sarah O’Connell Kalil

Sarah Kalil brings over three decades of medical device and diagnostic company executive experience to her current role as Chief Executive Officer of CoreMap. She co-founded the company in 2017 with the mission of improving patient outcomes by delivering advanced diagnostic technology for mapping complex cardiac arrhythmias to clinicians and their patients. Sarah secured funding and led proof of concept and feasibility testing to demonstrate the Company’s value proposition. Under Sarah’s leadership, CoreMap secured over $50m in funding from leading investors, attracted world-class engineering and science talent, achieved proof of concept by completing over 60 pre-clinical studies and is currently conducting a multi-national randomized controlled trial to demonstrate improved outcomes for patients with AF. The Company has secured a comprehensive patent portfolio, and received a National Science Foundation research grant award.

Before co-founding CoreMap, Sarah served as the Chief Operating Officer at T2 Biosystems, where she guided the company through de novo FDA clearance of a nuclear magnetic resonance sepsis diagnostic technology, and the company’s subsequent IPO. Prior to T2, Sarah also held the role of Chief Operating Officer of Interlace Medical where she oversaw FDA clearance of the MyoSure product line and subsequent acquisition by Hologic. Sarah remained with Hologic scaling the MyoSure product line to $80m in sales in its first 24 months as well as supporting the execution and integration of M&A transactions. Sarah also served on the Board of Directors at Cadence, Inc. for four years leading to its sale, and at Juniper Biomedical from its early formation years. 

Sarah is a longtime advocate and mentor for entrepreneurs and women in science and business. In recent years, she has leveraged her expertise in board governance, clinical studies, FDA negotiations, fundraising, product development, regulatory strategy, team building, technology transfer and product scale-up to help inventors build companies dedicated to commercializing clinical solutions for large patient populations with unmet needs. In recent years Sarah has served as an advisor or board member to many pre-commercial medical device technology companies across sectors including med-tech AI, wireless peripheral neural stimulation, early-stage blood sample cancer diagnostics, and a diagnostic test to manage risk of cardiovascular disease.

Sarah earned a BS degree in Engineering from the University of Vermont and an MSJ degree in pharmaceutical and medical device law from Seton Hall University School of Law. She is a past member of the Executive Council for the Center for Women’s Cancers at the Dana Farber Cancer Institute, a current director of the Stowe Land Trust, and resides in Vermont with her husband David of 34 years and her two dogs Lucy and Scout. Sarah has a love of family and enjoys year-round outdoor sports.